Table 1. Summary of studies reporting ERCC1 expression and outcomes in non-small cell and small-cell lung cancer patients.
| Study | No of patients* | Clinical trial | Stage | Chemotherapy | ERCC1 Method | % high ERCC1 expression |
| NSCLC | ||||||
| Lord et al. [39] | 56 | Yes | IIIB-IV | Cisplatin/gemcitabine | RTqPCR | 50 |
| Rosell et al. [38] (A) | 31 | Yes | IIIB-IV | Cisplatin/gemcitabine/vinorelbine | RTqPCR | 52 |
| Rosell et al. [38] (B) | 29 | Yes | IIIB-IV | Gemcitabine/vinorelbine and vinorelbine/ifosfamide | RTqPCR | 41 |
| Simon et al. [37] | 51 | No | Resected IA-IIIB | Noneƒ | RTqPCR | ∼50 |
| Olaussen et al. [36] (A) | 389 | Yes | I-III | Adjuvant cisplatin/etoposide or cisplatin/vinca alkaloid | IHC | 42 |
| Olaussen et al. [36] (B) | 372 | Yes | I-III | None | IHC | 46 |
| Ceppi et al. [35] | 61 | Yes | IIIA-IV | Cisplatin/gemcitabine or gemcitabine monotherapy | RTqPCR | 56 |
| Booton et al. [31] | 66 | Yes | IIIA-IV | Carboplatin/docetaxel or MIC or MVP | RTqPCR | 50 |
| Zeng et al. [34] | 184 | No | Resected IA-IB | None | IHC | 50 |
| Rosell et al. [30] | 126 | No | Resected I-IIIA | None | RTqPCR | 50 |
| Azuma et al. [33] | 67 | No | Recurrent | Platinum doublet | IHC | 43 |
| Lee et al. [29] | 130 | No | Resected I-III | None | IHC | 62 |
| Fujii et al. [32] (A) | 15 | Yes | IIIA-IIIB | Neo-adjuvant cisplatin/irinotecan | IHC | 47 |
| Fujii et al. [32] (B) | 20 | Yes | IIIA-IIIB | Neo-adjuvant chemoRT; cisplatin/docetaxel | IHC | 65 |
| Okuda et al. [28] (A) | 90 | No | Resected I-IV | Neo-adjuvant or adjuvant platinum doublet | IHC | 43 |
| Okuda et al. [28] (B) | 59 | No | NS | None | IHC | 34 |
| Hwang et al. [21] | 68 | No | IIIA | Neo-adjuvant chemoRT; platinum doublet | IHC | 46 |
| Lee et al. [41] | 50 | No | IIIB/IV/recurrent | Platinum doublet | IHC | 56 |
| Azuma et al. [22] | 34 | No | IIB-IIIB | Concurrent chemoRT; cisplatin/docetaxel | IHC | 47 |
| Ota et al. [26] | 156 | No | IV | Platinum doublet | IHC | 64 |
| Wang et al. [42] | 124 | No | IIIB-IV | Cisplatin doublet | IHC | 35 |
| Holm et al. [43] | 163 | No | Inoperable IIB-IV | Carboplatin/gemcitabine | IHC | 43 |
| Jeong et al. [44] | 39 | No | III | ChemoRT; cisplatin doublet or triplet | IHC | 31 |
| Bartolucci et al. [24] | 54 | No | Resected IB-IIB | None | RTqPCR | 50 |
| SCLC | ||||||
| Ceppi et al. [27] (A) | 40 | No | Extensive | Cisplatin/carboplatin and etoposide | RTqPCR | 51⌋ |
| Ceppi et al. [27] (B) | 45 | No | Limited | Cisplatin/carboplatin and etoposide | RTqPCR | |
| Lee et al. [23] (A) | 37 | No | Extensive | Platinum doublet | IHC | 17⌋ |
| Lee et al. [23] (B) | 40 | No | Limited | Platinum doublet | IHC | |
| Kim et al. [40] | 130 | No | Extensive (86%) | Platinum-based combination | IHC | 28 |
RTqPCR, reverse transcriptase quantitative polymerase chain reaction; IHC, immunohistochemistry; MIC, mitomycin/ifosfamide/cisplatin; MVP, mitomycin/vinblastine/cisplatin; chemoRT, chemoradiotherapy; NS, not stated;
*, number of patients assessable for ERCC1 expression and overall survival;
ƒ
, one patient received adjuvant chemoradiotherapy;
⌋
, % high ERCC1 expression overall (data not stated for subgroups separately).